Climb Bio (CLYM) Gains from Sales and Divestitures (2021 - 2026)
Climb Bio (CLYM) reported Gains from Sales and Divestitures of $563.0 for Q1 2026, down 99.86% on a YoY basis from $401500.0 in Q1 2025, and down 99.94% quarter-over-quarter from $929563.0 in Q4 2025.
Climb Bio (CLYM) Gains from Sales and Divestitures (2021 - 2026) Analysis & Trends
Climb Bio has reported Gains from Sales and Divestitures for 6 years, with the latest figure at $563.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Sales and Divestitures fell 99.86% year-over-year to $563.0; the trailing twelve-month figure through Mar 2026 stood at $563.0 (down 99.86% YoY), and the FY2025 full-year result was $929563.0, up 131.52% from the prior year.
- Gains from Sales and Divestitures for Q1 2026 stood at $563.0, down from $929563.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $929563.0 in Q4 2025, with the low at $563.0 in Q1 2026.
- Historically, Gains from Sales and Divestitures has averaged $274514.1 across 5 years, with a median of $124737.0 in 2023.
- Annual changes were most pronounced in 2025 — Gains from Sales and Divestitures surged 1533.51% — and 2026, when it plunged 99.86%.
- Climb Bio's Gains from Sales and Divestitures stood at $154869.0 in 2022, then dropped by 19.46% to $124737.0 in 2023, then surged by 221.88% to $401500.0 in 2024, then surged by 131.52% to $929563.0 in 2025, then tumbled by 99.94% to $563.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $563.0 (Q1 2026), $929563.0 (Q4 2025), and $929001.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Climb Bio | 740.73 Mn | 740.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 563.00 |
| Mar 31, 2026 | 563.00 |
| Dec 31, 2025 | 929,563.00 |
| Dec 31, 2025 | 929,563.00 |
| Sep 30, 2025 | 929,001.00 |
| Sep 30, 2025 | 929,001.00 |
| Jun 30, 2025 | 508,666.00 |
| Jun 30, 2025 | 508,666.00 |
| Mar 31, 2025 | 401,500.00 |
| Mar 31, 2025 | 401,500.00 |
| Dec 31, 2024 | 401,500.00 |
| Dec 31, 2024 | 401,500.00 |
| Sep 30, 2024 | 401,500.00 |
| Sep 30, 2024 | 401,500.00 |
| Jun 30, 2024 | 401,500.00 |
| Jun 30, 2024 | 401,500.00 |
| Mar 31, 2024 | 24,579.00 |
| Mar 31, 2024 | 24,579.00 |
| Dec 31, 2023 | 124,737.00 |
| Dec 31, 2023 | 124,737.00 |